Design Therapeutics
Biotechnology ResearchView the employees at
Design Therapeutics-
Kirk Ryan Law, MS Director, Data Management at Design Therapeutics
-
Nolensville, Tennessee, United States
-
Top 5%
Julie Burgess Chief Accounting Officer at Design Therapeutics-
San Diego, California, United States
-
Top 5%
Jim Kerr Sr Vice President of Product Development-
San Diego, California, United States
-
Top 5%
Overview
We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.
-